Ifyber

Executive Summary

Ifyber is a preclinical contract research organization (CRO) based in Cambridge, Massachusetts, founded in 2016. The company specializes in custom method development and testing services at the intersection of chemistry, biology, and materials science. Its client base spans medical devices, wound care, diagnostics, and specialty textiles, positioning it as a niche service provider for early-stage product development. Operating in the preclinical stage, Ifyber supports clients in navigating regulatory and technical challenges, though it does not develop its own therapeutic pipeline. As a private CRO with limited public information, Ifyber's financials, client concentration, and growth trajectory remain opaque. The company faces competition from larger CROs but may carve a niche in specialized materials and biologics testing. Without disclosed funding rounds or revenue data, assessing its market traction is challenging. Ifyber's success hinges on expanding its service portfolio, securing recurring contracts, and differentiating in a commoditized CRO landscape.

Upcoming Catalysts (preview)

• TBDNew client partnerships or contract wins in medical devices or wound care50% success
• TBDExpansion of testing capabilities or facility upgrades40% success